Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat

Pharmacotherapy - United States
doi 10.1002/phar.1671
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Histone Deacetylase Inhibitors in Multiple Myeloma

Hematology Reports
Hematology
2009English

Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

New Insights Into the Treatment of Multiple Myeloma With Histone Deacetylase Inhibitors

Current Pharmaceutical Design
Drug DiscoveryPharmacology
2012English

Carfilzomib for Relapsed or Refractory Multiple Myeloma

The Lancet Oncology
Oncology
2018English

Emerging Role of Carfilzomib in Treatment of Relapsed and Refractory Lymphoid Neoplasms and Multiple Myeloma

Core Evidence
MedicineReviewsReferencesPharmacology
2011English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research
Medicine
2010English

Thioredoxin in Cancer—Role of Histone Deacetylase Inhibitors

Seminars in Cancer Biology
Cancer Research
2006English

Histone Deacetylase Inhibitors Valproic Acid and Vorinostat Enhance Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Phagocytosis

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Inhibitors of Histone-Deacetylase

Journal of Applied Biomedicine
GeneticsMolecular BiologyPharmacologyBiochemistryBiological SciencesToxicologyMedicineAgriculturalNeurosciencePharmaceutics
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy